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Background: This study was designed to investigate leptin levels in the fluid in ovarian endometriomas (OEs) and
to compare the expression of leptin and its receptors (OBR) in ovarian tissue affected by endometrioma in infertile
women to its expression in the normal ovarian tissue of fertile controls without endometriosis.
Methods: In this case–control observational study, ovarian tissue, blood samples and peritoneal fluid were obtained
from 20 women (10 fertile controls without endometriosis or any ovarian disease, who were undergoing tubal
ligation surgery, and 10 infertile women with severe endometriosis and OE). The ovarian endometriomal fluid (EF)
was aspirated, and peritoneal-implant (PI) biopsies were performed. The tissues removed during the surgeries were
immediately frozen in liquid nitrogen to determine expression levels by western blot and leptin levels by ELISA.
Results: OBR was expressed at higher levels in the ovarian tissue affected by endometrioma than in the normal
ovarian tissue (control = 0.38 ± 0.05, study = 0.60 ± 0.09, p = 0.03), but there was no significant difference in leptin
levels between these groups (control = 0.57 ± 0.1, study = 0.35 ± 0.1, p = 0.18). Positive and significant correlations
were observed between leptin and OBR in the OE (r = 0.85, p = 0.004) and in the PI (r = 0.87, p = 0.001). ELISA results
demonstrate a greater leptin concentration within the EF compared with the serum and the PF (serum = 14.25 ±
1.63, PF = 5.98 ± 2.0, EF = 73.8 ± 16.2, p = 0.0001), but there was no correlation between these variables. A positive,
significant and strong correlation was observed between PF leptin levels and the expression of leptin and OBR in
PI (leptin: r = 0.78, p = 0.007/OBR: r = 0.68, p = 0.04) and between the EF leptin levels and the expression of leptin
and OBR in the OE (leptin: r = 0.88, p = 0.008/OBR: r = 0.89, p = 0.005).
Conclusions: These data suggest that leptin may play an important role in the physiopathology of OE through a
modulatory interaction with its active receptor.
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Leptin, the product of the ob/ob gene [1] is an adipocyte-
derived protein that regulates food intake and energy ex-
penditure. Accumulating evidence shows that it is also a
crucial factor in the endocrine regulation of several
physiologic processes, including inflammation, angio-
genesis and reproductive functions [2].* Correspondence: carolzendron@hotmail.com
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stated.Endometriosis is a chronic and progressive disease
associated with abnormal peritoneal and endometrial
production of proinflammatory cytokines, growth factors
and angiogenic factors [3], which may interfere with the
function of the reproductive system.
Due to its inflammatory and angiogenic properties, as
well as its possible involvement in reproductive abnor-
malities at both the central and the gonadal levels [4],
leptin has been extensively studied in patients with
endometriosis. A recent report demonstrated that leptinal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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tion, early vascular recruitment, and the maintenance of
neoangiogenesis in a murine model of endometriosis [5].
Another report showed that the leptin receptor (OBR) is
induced in endometriosis and that leptin stimulates the
growth of endometriotic epithelial cells through the
JAK2/STAT3 and ERK pathways [6].
Endometrioma is a localized form of endometriosis that
primarily affects the ovaries and occurs in approximately
17-40% of women with endometriosis [7]. The pathoge-
nesis of endometriotic ovarian cysts remains controversial,
and their treatment remains a challenge. Ovarian endome-
triomas (OEs) form through progressive invagination of
the ovarian cortex [8], suggesting that they are false cysts
and that the cyst wall is made of the same material as the
ovarian cortex [9]. OEs equal to or larger than 3 cm re-
spond poorly to medical therapy [10], and both OEs and
their surgical removal are associated with a significant
reduction in the ovarian reserve, with negative effects
on fertility [11].
The expression of leptin and its receptor has been de-
scribed in OEs [12]. Small studies have demonstrated an
increased concentration of this peptide in the peritoneal
fluid (PF) of patients with endometriosis [13], and it is
present at higher levels in women with peritoneal endo-
metriosis than in women with ovarian endometriosis.
Based on these findings, Alvigii suggests that patients
with OE may show increased leptin levels in the ‘cho-
colate’ fluid in the endometrioma [14], but there is insuf-
ficient evidence to support this hypothesis.
As suggested by previous studies, leptin has a role in
the pathogenesis of OE via inflammatory and angiogenic
effects; however, no study had compared the expression
of this protein in human ovarian tissue affected by endo-
metrioma to its expression in normal ovarian tissue, and
its presence in the chocolate fluid in OEs has never been
investigated.
This study was designed to compare the expression of
leptin and its receptors in ovarian tissue affected by
endometrioma in infertile women to its expression in
the normal ovarian tissue of fertile controls not affected
by endometriosis. We also examine, for the first time,
leptin levels in the ovarian endometriomal fluid (EF).
Methods
Patient enrollment
The study group consisted of ten patients who under-
went laparotomy or laparoscopy for adnexal masses and
infertility (n = 10). The inclusion criteria for this group
were at least one year of primary infertility; regular cy-
cles before starting hormonal treatment to control pain
associated with endometriosis; unilateral or bilateral OE
and normal male fertility. Peritoneal endometriotic le-
sions were observed in all patients in the study group.The control group was composed of ten women with
proven fertility from the family-planning program of the
same hospital who were undergoing mini-laparotomy or
laparoscopy for tubal ligation and without surgical evi-
dence of endometriosis or any ovarian pathology. All pa-
tients in the control group had a normal pelvic cavity.
The surgeries were performed between February 8, 2013,
and July 31, 2013, at the Department of Gynecology of
the Pedro Ernesto University Hospital, Rio de Janeiro.
All of the subjects were of reproductive age and were
receiving hormonal therapy for clinical treatment of pain
associated with endometriosis or for contraception (in the
control group). All enrolled patients had a body mass
index (BMI) of 20–30 kg/m2. The exclusion criteria were
clinical and/or echographic indications of polycystic ovar-
ian disease, diabetes and systemic hepatic or thyroid in-
flammatory disease and surgical evidence of any other
ovarian pathology. The study was approved by the local
ethics committee (Research Ethics Committee of the
Pedro Ernesto University Hospital (CEP - HUPE), Rio de
Janeiro, Brazil), and written informed consent was ob-
tained from all patients before the procedures.
Tissue specimens
Serum samples were obtained before anesthesia. PF was
aspirated from the posterior cul-de-sac at the beginning
of surgery. A small wedge resection of the intact and
healthy ovary was performed in the control group. The
ovarian EF was aspirated, and the OE was removed,
always by the same surgeon by cystectomy. Peritoneal
biopsies were performed in the study group to provide
histological confirmation of endometriosis and data for
the study.
The extent of endometriosis was scored according to
the revised standards of the American Society of Repro-
ductive Medicine [15]. A portion of each sample was
sent to a pathologist, who reviewed the ovarian endome-
triomal specimens to confirm the presence of cyst wall-
lining cells and ovarian-cortex cells, and normal ovary
specimens were examined to confirm the absence of
pathology. All samples used in the study were immedi-
ately frozen in liquid nitrogen and stored at – 80°C.
Western blotting
Approximately 500 mg of tissue was homogenized in
500 μl of lysis buffer containing 1% NP-40 (Amresco,
Ohio, USA) and a protease-inhibitor mix (Sigma), then
centrifuged at 9700 rpm at 4°C. The protein concentration
was measured by fluorometry (Qubit 2.0, Life Technologies
Corporation, CA, USA), and 20-μg aliquots were ap-
plied to 8% SDS-polyacrylamide gel and submitted to
vertical electrophoresis (150 mA, 50 V for 90 min), then
transferred to nitrocellulose membranes (80 mA, 4 V
for 90 min) in a semi-dry transfer apparatus. The
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bodies (Santa Cruz, CA, USA) to leptin (1:500) and
OBR (1:200). The expression of the proteins under study
was normalized against the expression of β-actin. The
bands were visualized by chemiluminescence (ECL,
Amersham Biosciences, Piscataway, NJ, USA), and do-
cumented on the ChemiDoc MP System, Bio-Rad (Life
Science Research, USA). All bands were quantified
using Image J software 1.42q, USA.
Determining levels of leptin
The concentration (ng/ml) of leptin in serum, PF and
EF was determined by ELISA (Millipore Corporation
Billerica, MA, USA). The spectrophotometer was read
according to the manufacturer’s specifications.
Statistical analyses
We used GraphPad Prism (version 6.0, GraphPad Software,
CA, USA) to test data for normality and homogeneity of
variances. Student’s t-test was used to compare the two
groups, and analysis of variance was used to compare
three groups. Pearson’s correlation was performed to
examine the correlations between some parameters. All
results are reported as the mean ± standard error of the
mean (SEM), and P-values < 0.05 were considered statis-
tically significant.
Results
The age and BMI of the patients are expressed as the
mean ± the standard error (Table 1). All patients were
classified as having stage-IV (severe) endometriosis, and
in all patients in the study group, surgery was indicatedTable 1 Baseline characteristics of participants
Control Study
Demographic and anthropometric variables
N 10 10
Age (yr) 31.5 +/− 1.63 30.5 +/− 1.50
Body mass index (kg/m2) 23.4 +/− 0.88 23.6 +/− 0.57
Stage of disease
Stage I (minimal) - 0 (0)
Stage II (mild) - 0 (0)
Stage III (moderate) - 0 (0)
Stage IV (severe) - 10 (100)
Hormonal therapy
Estrogen + progesterone 6 (60) 8 (80)
Progesterone 4 (40) 2 (20)
Indication for surgery
Infertility + adnexal mass - 10 (100)
Tubal ligation 10 (100) -
Values in parentheses are percentages.
Age and BMI are expressed as the mean +/−.by infertility associated with an adnexal mass. In the
control group, all patients underwent surgery for tubal
ligation. One inclusion criterion was the use of hormone
therapy; 80% of patients in the study group and 60% of
patients in the control group were using a combined
oral contraceptive (estrogen and progesterone), and the
remaining patients in both groups were using isolated
progestin therapy.
Western blots revealed no significant decrease in
leptin levels in the study group (control = 0.57 ± 0.1,
study = 0.35 ± 0.1, p = 0.18), as shown in Figure 1A. In
contrast, the receptor (Figure 1B) was expressed at sig-
nificantly higher levels in the same group (control = 0.38
± 0.05, study = 0.60 ± 0.09, p = 0.03). In the study group,
there was no significant difference in the expression of
leptin (PI = 0.40 ± 0.09, OE = 0.35 ± 0.11, p = 0,71) and its
receptors (PI = 0.69 ± 0.16, OE = 0.60 ± 0.09, p = 0.61) be-
tween patients with ovarian OE and those with perito-
neal implants (PI; Figure 1C and D).
There was no difference in serum (control = 14.79 ±
2.63, study = 14.25 ± 1.63, p = 0.87) and in PF (control =
6.68 ± 1.21, study = 5.98 ± 2.0, p = 0.76) leptin levels in the
control group compared to the study group (Figure 2A).
The leptin levels in the serum, PF and EF of patients in
the study group are presented in Figure 2B. The leptin
levels in the EF were significantly higher than those in the
serum and PF (serum = 14.25 ± 1.63, PF = 5.98 ± 2.0, EF =
73.8 ± 16.2, p = 0.0001).
Leptin levels in the serum, PF and EF did not show
any correlation between each other, in patients with OE.
The correlation between leptin and OBR are presented
in Table 2. A positive and significant correlation was
observed between leptin and OBR expression in the OE
(r = 0.85, p = 0.004) and PI (r = 0.87, p = 0.001) of pa-
tients in the study group, but this relationship was not
observed in the control group (r = 0.41, p = 0.22). There
was no correlation between leptin levels in the PF and
the expression of leptin and OBR in the OE (leptin =
0.75, p = 0.08/OBR: r = −0.17, p = 0.71; Table 2), and this
correlation was positive and significant for PI (leptin: r =
0.78, p = 0.007/OBR: r = 0.68, p = 0.04). Leptin levels in
the EF correlated strongly and positively with the expres-
sion of leptin and OBR in the OE (leptin: r = 0.88,
p = 0.008/OBR: r = 0.89, p = 0.005; Table 2).
Discussion
This observational case–control study showed that OBR
is expressed at higher levels in ovarian tissue affected by
endometrioma in infertile patients than in the normal
ovarian tissue of fertile controls not affected by endo-
metriosis. In contrast, leptin expression was slightly
lower in the study group. These findings have never pre-
viously been described in the literature. Previous studies
have used normal endometrium or PI in patients with
Figure 1 Expression of leptin and the leptin receptor in the control and ovarian endometrioma groups. Expression of leptin (A) and the
leptin receptor (OBR; B) in the control and ovarian endometrioma (OE) groups; and expression of leptin (C) and the leptin receptor (OBR; D) in
endometriotic peritoneal implants (PI) and in ovarian endometrioma (OE) in the study group. Data are expressed as the mean +/− SEM per
group of 10 subjects.
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mal ovarian tissue. Wu et al. detected the leptin tran-
script and protein in both PI and OE and found no
difference in the quantity of leptin transcript between
these two groups [12]; however, the expression of leptin
and OBR mRNA is increased in OEs compared with the
normal endometrium. We also compared the expression
of leptin and its receptors in the OE to its expression in
PI in patients in our study group; as in the previous
study, we found no difference between these two groups.Figure 2 Leptin levels in the control and study groups. Leptin levels in
(A). Leptin levels in the serum, peritoneal fluid (PF) and endometriomal flu
mean +/− SEM per group of 7 subjects.Recently, the expression of leptin and OBR was found to
be significantly higher in the OE than in normal endo-
metrium [16]. Moreover, this same report showed that
treatment of endometriotic cells with leptin induced the
expression of OBR mRNA, which suggests autocrine
and paracrine involvement of the leptin system in endo-
metriosis. These data suggest that endometriosis im-
plants are both a potential source of leptin production
and a potential target of its action. Therefore, we suggest
that ovarian tissue affected by endometrioma might beserum and the peritoneal fluid (PF) in the control and study groups
id (EF) of patients in the study group (B). Data expressed as the
Table 2 Correlation among leptin and its receptors in
ovarian tissue and peritoneal implants
Correlation coefficient P value
Ovarian tissue
Leptin OE and OBR OE 0.85 0.004
Leptin Control and OBR Control 0.41 0.22
Leptin OE and PF leptin 0.75 0.08
OBR OE and PF leptin - 0.17 0.71
Leptin OE and EF leptin 0.88 0.008
OBR OE and EF leptin 0.89 0.005
Peritoneal implants
Leptin PI and OBR PI 0.87 0.001
Leptin PI and PF leptin 0.78 0.007
OBR PI and PF leptin 0.68 0.04
Pearson correlation analysis. OE ovarian endometrioma, OBR leptin receptor, PF
peritoneal fluid, EF endometriomal fluid, PI peritoneal implants.
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and might also have a greater capacity for synthesis of
this peptide.
Although these groups are small, their relative homo-
geneity is a strength of this study. All women in the
study group had infertility and stage-IV (severe) endo-
metriosis. The stage of endometriosis is not correlated
with the presence or severity of symptoms, but infertility
is very likely in patients with stage IV endometriosis
[15]. All women in the control group were fertile and
underwent surgery for tubal ligation. Most studies in-
clude different stages of endometriosis and other pelvic
diseases, such as uterine leiomyoma or cancer in the
controls, introducing potential bias. All women in this
study were receiving hormone therapy, which provided
a stable hormonal environment and eliminated the
possibility of fluctuations in leptin levels during the
menstrual cycle.
Our findings demonstrated no difference in PF leptin
levels in infertile women with severe endometriosis and
OE compared to fertile controls not affected by endo-
metriosis and similar serum leptin levels in both groups.
Serum leptin levels appear to be similar in women with
and without endometriosis at any stage [17]. In contrast,
small studies have shown that PF leptin is significantly
higher in endometriosis patients compared to those with-
out the disease and the presence of OE had no significant
main effect on leptin concentration. [18]. PF leptin levels
were significantly higher in infertile women with endo-
metriosis than in patients with pelvic pain and endometri-
osis [19] or unexplained infertility [20]. Nevertheless,
PF leptin levels were inversely correlated with the
stage of disease, which could explain our result [21].
PF leptin levels in patients with OE are elevated due to
peritoneal endometriotic lesions or OE; the cause ispresently unknown. One report showed that patients with
“superficial” endometriomas had significantly higher levels
of leptin in the PF than did patients with “deep” OEs [14].
Another report found that patients with PI at all stages of
endometriosis showed higher PF leptin concentrations
than patients with no implant, and the presence of OE
had no significant main effect on leptin concentration
[18]; however, isolated ovarian endometriosis is rare, as it
is considered a marker for severe, deeply infiltrating endo-
metriosis [22]. Furthermore, many endometriotic lesions,
especially diaphragmatic and bowel lesions or atypical, non-
pigmented PI, may not be visualized during surgery [23,24].
It is thus extremely difficult to exclude this variable.
Thus, peritoneal disease, but not ovarian endometriotic
cysts, influences the concentration of leptin in PF in
endometriosis; these two types of endometrial lesions may
have different pathogenic mechanisms and distinct leptin-
biosynthetic capacities [18]. Alternatively, the leptin may
be sequestered into the cystic fluid of the OE [12]. We
found increased levels of leptin in the EF compared to the
PF of patients with both PI and OE; these variables were
not correlated with each other. The increased levels of lep-
tin in the EF may be the result of the slight decrease in
leptin expression in ovarian tissue affected by endome-
trioma; this protein may have been secreted into the endo-
metrioma and diffused in the chocolate fluid. In accordance
with previous data, we believe that the concentration of
leptin in the PF is influenced by PI; we also suggest that
OEs influence leptin concentration in the EF.
Our findings show a strong positive correlation be-
tween the expression of leptin and OBR in OE and PI. A
significant positive correlation was observed between
leptin and OB-RL transcripts in ectopic endometria
[25]. Although the difference was not statistically signifi-
cant, previous data showed a modest positive correlation
between the expression of leptin and that of OBR in pa-
tients with OEs [16]. Furthermore, these same authors
demonstrated that leptin treatment induced OBR ex-
pression in endometriotic cells. We also demonstrated a
significant positive correlation between PF leptin levels
and the expression of leptin and OBR in PI, but this cor-
relation was not observed in OE. In contrast, the expres-
sion of leptin and its receptor in OE correlated strongly
and positively with leptin levels in EF. In contrast to our
results, a significant negative correlation was observed
between OBR transcripts and PF leptin levels in ectopic
endometrium [25]. These significant positive correla-
tions suggest that OBR may be induced in OE and PI by
leptin levels in EF and PF, respectively.
Given the presence of large quantities of leptin in the
OE, it remains unknown whether this inflammatory fac-
tor contributes to both the decreased oocyte reserve and
the quality of the affected ovary. A prospective study re-
vealed that elevated intra-ovarian leptin concentrations
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response, reduced follicle maturation, poorer embryo
quality and a lower likelihood of successful pregnancy,
suggesting that leptin modulates embryo quality and
may serve as a sensitive marker of IVF outcomes [26].
We thus suggest that the increased leptin levels in the
ovarian EF may play an important role in the reproduct-
ive abnormalities that accompany this disease, but fur-
ther studies are required to support this hypothesis.
Disorders related to leptin deficit and leptin overabun-
dance required the development of drugs that activate or in-
hibit the OBR [27]. The administration of the pegylated
leptin peptide receptor antagonist (LPrA) or nonfunctional
OBR (LeprdB) in a rat model of endometriosis demon-
strated that disruption of leptin signaling can inhibits the
establishment and development of endometriosis-like lesions
that resemble peritoneal endometriotic foci [5]. A leptin mu-
tant with antagonistic properties and other proteins that
block leptin activity open up new possibilities for research
and, eventually, therapy [28] for OE and similar diseases,
which do not respond well to any available medication.
Conclusion
In summary, this study shows that the expression of OBR is
higher in the ovarian tissue affected by OE in infertile pa-
tients than in the normal ovarian tissue of fertile controls
not affected by endometriosis. There was a positive and sig-
nificant correlation between leptin and OBR expression in
the OE and PI. We also demonstrated the presence of
high levels of leptin in the chocolate fluid in the OE, wich
correlated strongly and positively with the expression of
leptin and OBR in the OE, while leptin levels in PF corre-
lated with the expression of leptin and OBR in PI. These
data suggest that leptin may have an important role in the
physiopathology of OE through a modulatory interaction
with its active receptor.
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